Other Milestones. (i) if on or before the Back-End Date, Parent (A) receives funding of at least twenty million dollars ($20,000,000) from a Governmental Entity for development of ACER-2820 for the treatment of any indication or indications (the “ACER-2820 Development Funding”) and, within three (3) years of the date of the ACER-2820 Development Funding, Parent or its Affiliate either (x) grants a license to a third party under the intellectual property assets owned by Target relating to ACER-2820 (including U.S. Pat. Pub. No. 2022/0177469, any patent issuing from such application and any subsequently filed patent application claiming priority to such patent application) (the “ACER-2820 IP Assets”) for purposes of developing and commercializing ACER-2820 or (y) sells such ACER-2820 IP Assets to a third party or (B) Parent or its Affiliate obtains FDA Approval for use of ACER-2820 for treatment of any indication, then a Milestone Payment equal to the greater of (x) 10% of the total cash consideration paid to the Parent or its Affiliate for the license or sale of the ACER-2820 IP Assets or (y) $5,000,000 shall be payable in respect of such Milestone.
Other Milestones. (Comment on the status of the remaining milestones currently being worked on by the project team) Milestone number Status Comments
Other Milestones. OV shall further pay to LP the minimum of either (i) [***] percent ([***]%) of any milestone payments OV receives from a Program Acquirer for clinical development events other than events under Section 6.2(a)-(c) above (the Clinical Development Events), or (ii) a one-time payment of [***] U.S dollars ($[***]), whichever is higher. In the event of an Opt-In by LP, such additional payments under this subsection (g) shall increase to either (I) [***] percent ([***]%) of any clinical development milestone payments OV receives from a Program Acquirer for clinical development events other than events under Section 6.2(a)-(c) above (the Clinical Development Events), or (II) a one-time payment [***] of U.S dollars ($[***]), whichever is higher.
Other Milestones. The parties shall negotiate in good faith the commercially reasonable financial terms pertaining to payments for achievement of development milestones relating to Royalty-Bearing Products based on compounds resulting from the screening described in Section 4.1.6 or for uses of a Royalty-Bearing Product within the Field for purposes other than as a human therapeutic or prophylactic for [*****], which terms shall be set forth in a separate agreement.
Other Milestones. The occurrence of any of the following shall also constitute a Milestone Breach (as defined below):
Other Milestones. The other milestone has been made in a way to ensure Development, Operation and Management of the project as per the specifications listed below:
Other Milestones. 2.1 Without prejudice to the Outline Implementation Plan, the Contractor shall comply with all other timescales set out in the Call-Off Terms including the following:
Other Milestones. In the event that Parent or Surviving Company enters into or closes one or more Partnership Agreements with respect to the TAM Program (each, a “TAM Partnership”) within eighteen (18) months after the Closing, or in the event that Parent or Surviving Company enters into or closes one or more TAM Partnerships within the six (6) months immediately thereafter with a third party with whom Parent or the Surviving Company was in negotiations or discussions during the initial eighteen (18) month period, then the Stockholders shall receive a payment equal to fifty percent (50%) of any Upfront Payments received by Parent or its Affiliates under the terms of each TAM Partnership; provided, however, that any such payments shall not exceed $10.0 million in the aggregate. For the avoidance of doubt, each Milestone may be achieved only once and each Milestone Payment may be paid only one time, if at all. In addition, the first Milestone Payment to be paid (x) shall be accompanied by payment of the Closing Shortfall, if any, and (y) shall be reduced by Two Million Five Hundred Thousand Dollars ($2,500,000).
Other Milestones. 46 (f) ADDITIONAL COSTS RELATING TO CLINICAL MATTERS............................49 7. ROYALTIES; SHARING OF PROCEEDS....................................................49 (a) VACCINE PRODUCT AND NEW DC THERAPY PRODUCT ROYALTIES FOR THE BC FIELD, CP FIELD, OC FIELD AND CC FIELD..........................................49 (b) VACCINE PRODUCT AND NEW DC THERAPY PRODUCT ROYALTIES FOR THE TB FIELD, CP FIELD AND CT FIELD....................................................51 (c) ROYALTIES FOR ACTIVE IMMUNE RESPONSE PRODUCTS INCORPORATING HER2/NEU ANTIGEN(S) AND/OR MAMMAGLOBIN ANTIGEN(S).................................53 (d) ROYALTIES FOR EXISTING DC THERAPY PRODUCTS...............................56 (e) ROYALTIES FOR TDM PRODUCTS...............................................57 (f) ROYALTIES ON PRODUCTS COVERED BY SB PATENTS..............................58 (g) ROYALTIES FOR NEW T CELL-BASED PASSIVE IMMUNOTHERAPY PRODUCTS............58 (h) SHARING OF PROCEEDS......................................................59 (i) ROYALTY REPORTING AND OTHER ASPECTS......................................62 8.
Other Milestones. (i) For the sake of clarity, with respect to the making of milestone payments to Corixa by SB under this Agreement (other than payments for [***]), the following principles shall apply:
